Evidence map›Paper›PMID 32410376›Full record

ArticleCancer medicine2020

Mining the role of angiopoietin-like protein family in gastric cancer and seeking potential therapeutic targets by integrative bioinformatics analysis.

Cheng Tang, Erbao Chen, Ke Peng, Haiwei Wang, Xi Cheng, Yan Wang, Shan Yu, Yiyi Yu, Yuehong Cui, Tianshu Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Cheng TangDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.ORCID 0000-0002-5876-0315
Erbao ChenDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.
Ke PengDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.
Haiwei WangDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.ORCID 0000-0002-9675-4039
Xi ChengDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.
Yan WangDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.
Shan YuDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.
Yiyi YuDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.
Yuehong CuiDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.
Tianshu LiuDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, PR China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe indistinctive effects of antiangiogenesis agents in gastric cancer (GC) can be attributed to multifaceted gene dysregulation associated with angiogenesis. Angiopoietin-like (ANGPTL) proteins are secreted proteins regulating angiogenesis. They are also involved in inflammation and metabolism. Emerging evidences have revealed their various roles in carcinogenesis and metastasis development. However, the mRNA expression profiles, prognostic values, and biological functions of ANGPTL proteins in GC are still elucidated.

methodsWe compared the transcriptional expression levels of ANGPTL proteins between GC and normal gastric tissues using ONCOMINE and TCGA-STAD. The prognostic values were evaluated by LinkedOmics and Kaplan-Meier Plotter, while the association of expression levels with clinicopathological features was generated through cBioPortal. We conducted the functional enrichment analysis with Metascape.

resultsThe expression of ANGPTL1/3/6 was lower in GC tissues than in normal gastric tissues. High expression of ANGPTL1/2/4 was correlated with short overall survival and post-progression survival in GC patients. Upregulated ANGPTL1/2 was correlated with higher histological grade, non-intestinal Lauren classification, and advanced T stage, while ANGPTL4 exhibited high expression in early T stage, M1 stage, and non-intestinal Lauren classification.

conclusionsIntegrative bioinformatics analysis suggests that ANGPTL1/2/4 may be potential therapeutic targets in GC patients. Among them, ANGPTL2 acts as a GC promoter, while ANGPTL1/4's role in GC is still uncertain.

Indexed as

Computational BiologyAngiopoietin-Like Protein 1Angiopoietin-Like Protein 2Angiopoietin-Like Protein 3Angiopoietin-Like Protein 4Angiopoietin-Like Protein 6Angiopoietin-Like Protein 7Angiopoietin-Like Protein 8Angiopoietin-like ProteinsFemaleGastric MucosaHumansKaplan-Meier EstimateMaleNeoplasm ProteinsPeptide HormonesAngiopoietin-Like Protein 1Angiopoietin-Like Protein 2Angiopoietin-Like Protein 3Angiopoietin-Like Protein 4Angiopoietin-Like Protein 6Angiopoietin-Like Protein 7Angiopoietin-Like Protein 8Angiopoietin-like ProteinsANGPTL1 protein, humanANGPTL2 protein, humanANGPTL3 protein, humanANGPTL4 protein, humanANGPTL5 protein, humanANGPTL6 protein, humanANGPTL7 protein, humanANGPTL8 protein, humanNeoplasm ProteinsPeptide Hormonesangiopoietin-like proteinsfunctional enrichmentgastric cancerprognostic valuetranscriptional expression level

Identifiers

PMID32410376
PMCPMC7333835
OpenAlexW3026010813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.